PURPOSE: To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials. PATIENTS AND METHODS: Patients with HL treated at Stanford with at least 5 years of follow-up after completing therapy were identified from our database. Records were reviewed for outcome and development of t-AML/MDS. RESULTS: Seven hundred fifty-four patients treated from 1974 to 2003 were identified. Therapy varied across studies. Radiotherapy evolved from extended fields (S and C studies) to involved fields (G studies). Primary chemotherapy was mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or procarbazine, mechlorethamine, and vinblastine (PAVe) in S studies; MOPP, PAVe, vinblastine, bleomycin, and methotrexate (VBM), or doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in C studies; and VbM (reduced dose of bleomycin compared with VBM) or mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) in G studies. Cumulative exposure to alkylating agent (AA) was notably lower in the G studies compared with the S and C studies, with a 75% to 83% lower dose of nitrogen mustard in addition to omission of procarbazine and melphalan. Twenty-four (3.2%) of 754 patients developed t-AML/MDS, 15 after primary chemotherapy and nine after salvage chemotherapy for relapsed HL. The incidence of t-AML/MDS was significantly lower in the G studies (0.3%) compared with the S (5.7%) or C (5.2%) studies (P < .001). Additionally, in the G studies, no t-AML/MDS was noted after primary therapy, and the only patient who developed t-AML/MDS did so after second-line therapy. CONCLUSION: Our data demonstrate the relationship between the cumulative AA dose and t-AML/MDS. Limiting the dose of AA and decreased need for secondary treatments have significantly reduced the incidence of t-AML/MDS, which was extremely rare in the G studies (Stanford V era).
PURPOSE: To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials. PATIENTS AND METHODS: Patients with HL treated at Stanford with at least 5 years of follow-up after completing therapy were identified from our database. Records were reviewed for outcome and development of t-AML/MDS. RESULTS: Seven hundred fifty-four patients treated from 1974 to 2003 were identified. Therapy varied across studies. Radiotherapy evolved from extended fields (S and C studies) to involved fields (G studies). Primary chemotherapy was mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or procarbazine, mechlorethamine, and vinblastine (PAVe) in S studies; MOPP, PAVe, vinblastine, bleomycin, and methotrexate (VBM), or doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in C studies; and VbM (reduced dose of bleomycin compared with VBM) or mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) in G studies. Cumulative exposure to alkylating agent (AA) was notably lower in the G studies compared with the S and C studies, with a 75% to 83% lower dose of nitrogen mustard in addition to omission of procarbazine and melphalan. Twenty-four (3.2%) of 754 patients developed t-AML/MDS, 15 after primary chemotherapy and nine after salvage chemotherapy for relapsed HL. The incidence of t-AML/MDS was significantly lower in the G studies (0.3%) compared with the S (5.7%) or C (5.2%) studies (P < .001). Additionally, in the G studies, no t-AML/MDS was noted after primary therapy, and the only patient who developed t-AML/MDS did so after second-line therapy. CONCLUSION: Our data demonstrate the relationship between the cumulative AA dose and t-AML/MDS. Limiting the dose of AA and decreased need for secondary treatments have significantly reduced the incidence of t-AML/MDS, which was extremely rare in the G studies (Stanford V era).
Authors: F E van Leeuwen; A M Chorus; A W van den Belt-Dusebout; A Hagenbeek; R Noyon; E H van Kerkhoff; H M Pinedo; R Somers Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: M Loeffler; O Brosteanu; D Hasenclever; M Sextro; D Assouline; A A Bartolucci; P A Cassileth; D Crowther; V Diehl; R I Fisher; R T Hoppe; P Jacobs; J L Pater; S Pavlovsky; E Thompson; P Wiernik Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: E Brusamolino; A P Anselmo; C Klersy; M Santoro; E Orlandi; G Pagnucco; F Lunghi; R Maurizi-Enrici; C D Baroni; M Lazzarino; F Mandelli; C Bernasconi Journal: Haematologica Date: 1998-09 Impact factor: 9.941
Authors: P Carde; A Hagenbeek; M Hayat; M Monconduit; J Thomas; M J Burgers; E M Noordijk; A Tanguy; J H Meerwaldt; R Le Fur Journal: J Clin Oncol Date: 1993-11 Impact factor: 44.544
Authors: F E van Leeuwen; W J Klokman; A Hagenbeek; R Noyon; A W van den Belt-Dusebout; E H van Kerkhoff; P van Heerde; R Somers Journal: J Clin Oncol Date: 1994-02 Impact factor: 44.544
Authors: J F Boivin; G B Hutchison; A G Zauber; L Bernstein; F G Davis; R P Michel; B Zanke; C T Tan; L M Fuller; P Mauch Journal: J Natl Cancer Inst Date: 1995-05-17 Impact factor: 13.506
Authors: Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Sughosh Dhakal; Ranjana Advani; Leslie K Ballas; Bouthaina S Dabaja; Christopher R Flowers; Chul S Ha; Bradford S Hoppe; Nancy P Mendenhall; Monika L Metzger; John P Plastaras; Kenneth B Roberts; Ronald Shapiro; Sonali M Smith; Stephanie A Terezakis; Karen M Winkfield; Anas Younes; Louis S Constine Journal: Am J Clin Oncol Date: 2016-12 Impact factor: 2.339